nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—CYP2D6—Niacin—atherosclerosis	0.108	0.3	CbGbCtD
Metoclopramide—CYP2D6—Simvastatin—atherosclerosis	0.0856	0.237	CbGbCtD
Metoclopramide—CYP2D6—Lovastatin—atherosclerosis	0.0838	0.232	CbGbCtD
Metoclopramide—CYP2D6—Pravastatin—atherosclerosis	0.0838	0.232	CbGbCtD
Metoclopramide—Sexual dysfunction—Simvastatin—atherosclerosis	0.00754	0.0288	CcSEcCtD
Metoclopramide—Sexual dysfunction—Pravastatin—atherosclerosis	0.00682	0.026	CcSEcCtD
Metoclopramide—Blood disorder—Rosuvastatin—atherosclerosis	0.00639	0.0244	CcSEcCtD
Metoclopramide—Laryngeal oedema—Niacin—atherosclerosis	0.00605	0.0231	CcSEcCtD
Metoclopramide—Laryngospasm—Niacin—atherosclerosis	0.0052	0.0198	CcSEcCtD
Metoclopramide—Hepatotoxicity—Niacin—atherosclerosis	0.00503	0.0192	CcSEcCtD
Metoclopramide—Gynaecomastia—Rosuvastatin—atherosclerosis	0.00477	0.0182	CcSEcCtD
Metoclopramide—Gynaecomastia—Lovastatin—atherosclerosis	0.00404	0.0154	CcSEcCtD
Metoclopramide—Gynaecomastia—Simvastatin—atherosclerosis	0.00378	0.0144	CcSEcCtD
Metoclopramide—Fluid retention—Niacin—atherosclerosis	0.00369	0.0141	CcSEcCtD
Metoclopramide—Rash maculo-papular—Niacin—atherosclerosis	0.00353	0.0135	CcSEcCtD
Metoclopramide—Gynaecomastia—Pravastatin—atherosclerosis	0.00342	0.013	CcSEcCtD
Metoclopramide—Atrial fibrillation—Simvastatin—atherosclerosis	0.00324	0.0124	CcSEcCtD
Metoclopramide—Depression—Rosuvastatin—atherosclerosis	0.00298	0.0113	CcSEcCtD
Metoclopramide—Atrial fibrillation—Niacin—atherosclerosis	0.00297	0.0113	CcSEcCtD
Metoclopramide—Jaundice—Rosuvastatin—atherosclerosis	0.00291	0.0111	CcSEcCtD
Metoclopramide—Sunitinib—CSF1R—atherosclerosis	0.00287	1	CrCbGaD
Metoclopramide—Erectile dysfunction—Lovastatin—atherosclerosis	0.00261	0.00996	CcSEcCtD
Metoclopramide—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00256	0.00977	CcSEcCtD
Metoclopramide—Erectile dysfunction—Simvastatin—atherosclerosis	0.00244	0.00932	CcSEcCtD
Metoclopramide—Jaundice—Ezetimibe—atherosclerosis	0.00242	0.00922	CcSEcCtD
Metoclopramide—Depression—Simvastatin—atherosclerosis	0.00236	0.009	CcSEcCtD
Metoclopramide—Jaundice—Simvastatin—atherosclerosis	0.00231	0.00879	CcSEcCtD
Metoclopramide—Erectile dysfunction—Niacin—atherosclerosis	0.00224	0.00856	CcSEcCtD
Metoclopramide—Erectile dysfunction—Pravastatin—atherosclerosis	0.00221	0.00842	CcSEcCtD
Metoclopramide—Depression—Pravastatin—atherosclerosis	0.00213	0.00813	CcSEcCtD
Metoclopramide—Angioedema—Rosuvastatin—atherosclerosis	0.00213	0.00813	CcSEcCtD
Metoclopramide—Jaundice—Niacin—atherosclerosis	0.00212	0.00807	CcSEcCtD
Metoclopramide—Flushing—Lovastatin—atherosclerosis	0.00211	0.00804	CcSEcCtD
Metoclopramide—Jaundice—Pravastatin—atherosclerosis	0.00208	0.00795	CcSEcCtD
Metoclopramide—Flushing—Ezetimibe—atherosclerosis	0.00207	0.00788	CcSEcCtD
Metoclopramide—Flushing—Simvastatin—atherosclerosis	0.00197	0.00752	CcSEcCtD
Metoclopramide—Confusional state—Rosuvastatin—atherosclerosis	0.00192	0.00732	CcSEcCtD
Metoclopramide—Muscle spasms—Lovastatin—atherosclerosis	0.0019	0.00725	CcSEcCtD
Metoclopramide—Visual impairment—Niacin—atherosclerosis	0.00188	0.00717	CcSEcCtD
Metoclopramide—Muscle spasms—Ezetimibe—atherosclerosis	0.00186	0.00711	CcSEcCtD
Metoclopramide—Tremor—Lovastatin—atherosclerosis	0.00185	0.00706	CcSEcCtD
Metoclopramide—Visual impairment—Pravastatin—atherosclerosis	0.00185	0.00706	CcSEcCtD
Metoclopramide—Flushing—Niacin—atherosclerosis	0.00181	0.0069	CcSEcCtD
Metoclopramide—Angioedema—Lovastatin—atherosclerosis	0.00181	0.00689	CcSEcCtD
Metoclopramide—Flushing—Pravastatin—atherosclerosis	0.00178	0.00679	CcSEcCtD
Metoclopramide—Muscle spasms—Simvastatin—atherosclerosis	0.00178	0.00678	CcSEcCtD
Metoclopramide—Angioedema—Ezetimibe—atherosclerosis	0.00177	0.00675	CcSEcCtD
Metoclopramide—Leukopenia—Lovastatin—atherosclerosis	0.00177	0.00675	CcSEcCtD
Metoclopramide—Tremor—Simvastatin—atherosclerosis	0.00173	0.0066	CcSEcCtD
Metoclopramide—Insomnia—Rosuvastatin—atherosclerosis	0.00172	0.00656	CcSEcCtD
Metoclopramide—Palpitations—Ezetimibe—atherosclerosis	0.00171	0.00653	CcSEcCtD
Metoclopramide—Angioedema—Simvastatin—atherosclerosis	0.00169	0.00644	CcSEcCtD
Metoclopramide—Anxiety—Lovastatin—atherosclerosis	0.00168	0.00639	CcSEcCtD
Metoclopramide—Hypertension—Ezetimibe—atherosclerosis	0.00167	0.00638	CcSEcCtD
Metoclopramide—Leukopenia—Simvastatin—atherosclerosis	0.00165	0.00631	CcSEcCtD
Metoclopramide—Nervousness—Niacin—atherosclerosis	0.00165	0.00629	CcSEcCtD
Metoclopramide—Muscle spasms—Niacin—atherosclerosis	0.00163	0.00622	CcSEcCtD
Metoclopramide—Confusional state—Lovastatin—atherosclerosis	0.00163	0.0062	CcSEcCtD
Metoclopramide—Nervousness—Pravastatin—atherosclerosis	0.00162	0.00619	CcSEcCtD
Metoclopramide—Muscle spasms—Pravastatin—atherosclerosis	0.00161	0.00613	CcSEcCtD
Metoclopramide—Confusional state—Ezetimibe—atherosclerosis	0.0016	0.00608	CcSEcCtD
Metoclopramide—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00157	0.00598	CcSEcCtD
Metoclopramide—Anxiety—Simvastatin—atherosclerosis	0.00157	0.00598	CcSEcCtD
Metoclopramide—Tremor—Pravastatin—atherosclerosis	0.00157	0.00597	CcSEcCtD
Metoclopramide—Angioedema—Niacin—atherosclerosis	0.00155	0.00591	CcSEcCtD
Metoclopramide—Angioedema—Pravastatin—atherosclerosis	0.00153	0.00582	CcSEcCtD
Metoclopramide—Confusional state—Simvastatin—atherosclerosis	0.00152	0.0058	CcSEcCtD
Metoclopramide—Leukopenia—Niacin—atherosclerosis	0.00152	0.00579	CcSEcCtD
Metoclopramide—Urticaria—Rosuvastatin—atherosclerosis	0.00151	0.00577	CcSEcCtD
Metoclopramide—Oedema—Simvastatin—atherosclerosis	0.00151	0.00575	CcSEcCtD
Metoclopramide—Palpitations—Niacin—atherosclerosis	0.0015	0.00572	CcSEcCtD
Metoclopramide—Leukopenia—Pravastatin—atherosclerosis	0.0015	0.0057	CcSEcCtD
Metoclopramide—Insomnia—Lovastatin—atherosclerosis	0.00146	0.00556	CcSEcCtD
Metoclopramide—Hypertension—Pravastatin—atherosclerosis	0.00144	0.0055	CcSEcCtD
Metoclopramide—Dyspnoea—Lovastatin—atherosclerosis	0.00144	0.00548	CcSEcCtD
Metoclopramide—Insomnia—Ezetimibe—atherosclerosis	0.00143	0.00546	CcSEcCtD
Metoclopramide—Anxiety—Pravastatin—atherosclerosis	0.00142	0.00541	CcSEcCtD
Metoclopramide—Dyspnoea—Ezetimibe—atherosclerosis	0.00141	0.00538	CcSEcCtD
Metoclopramide—Hypersensitivity—Rosuvastatin—atherosclerosis	0.0014	0.00535	CcSEcCtD
Metoclopramide—Fatigue—Lovastatin—atherosclerosis	0.00139	0.0053	CcSEcCtD
Metoclopramide—Oedema—Niacin—atherosclerosis	0.00139	0.00528	CcSEcCtD
Metoclopramide—Confusional state—Pravastatin—atherosclerosis	0.00138	0.00524	CcSEcCtD
Metoclopramide—Asthenia—Rosuvastatin—atherosclerosis	0.00137	0.00521	CcSEcCtD
Metoclopramide—Insomnia—Simvastatin—atherosclerosis	0.00136	0.0052	CcSEcCtD
Metoclopramide—Oedema—Pravastatin—atherosclerosis	0.00136	0.0052	CcSEcCtD
Metoclopramide—Fatigue—Ezetimibe—atherosclerosis	0.00136	0.0052	CcSEcCtD
Metoclopramide—Tachycardia—Niacin—atherosclerosis	0.00135	0.00516	CcSEcCtD
Metoclopramide—Dyspnoea—Simvastatin—atherosclerosis	0.00135	0.00513	CcSEcCtD
Metoclopramide—Feeling abnormal—Lovastatin—atherosclerosis	0.00133	0.00507	CcSEcCtD
Metoclopramide—Feeling abnormal—Ezetimibe—atherosclerosis	0.0013	0.00497	CcSEcCtD
Metoclopramide—Diarrhoea—Rosuvastatin—atherosclerosis	0.0013	0.00497	CcSEcCtD
Metoclopramide—Fatigue—Simvastatin—atherosclerosis	0.0013	0.00496	CcSEcCtD
Metoclopramide—Hypotension—Niacin—atherosclerosis	0.00129	0.00494	CcSEcCtD
Metoclopramide—Urticaria—Lovastatin—atherosclerosis	0.00128	0.00489	CcSEcCtD
Metoclopramide—Body temperature increased—Lovastatin—atherosclerosis	0.00128	0.00486	CcSEcCtD
Metoclopramide—Dizziness—Rosuvastatin—atherosclerosis	0.00126	0.0048	CcSEcCtD
Metoclopramide—Urticaria—Ezetimibe—atherosclerosis	0.00126	0.00479	CcSEcCtD
Metoclopramide—Insomnia—Niacin—atherosclerosis	0.00125	0.00478	CcSEcCtD
Metoclopramide—Body temperature increased—Ezetimibe—atherosclerosis	0.00125	0.00477	CcSEcCtD
Metoclopramide—Feeling abnormal—Simvastatin—atherosclerosis	0.00124	0.00474	CcSEcCtD
Metoclopramide—Dyspnoea—Niacin—atherosclerosis	0.00124	0.00471	CcSEcCtD
Metoclopramide—Insomnia—Pravastatin—atherosclerosis	0.00123	0.0047	CcSEcCtD
Metoclopramide—Somnolence—Niacin—atherosclerosis	0.00123	0.0047	CcSEcCtD
Metoclopramide—Dyspnoea—Pravastatin—atherosclerosis	0.00122	0.00464	CcSEcCtD
Metoclopramide—Rash—Rosuvastatin—atherosclerosis	0.0012	0.00458	CcSEcCtD
Metoclopramide—Dermatitis—Rosuvastatin—atherosclerosis	0.0012	0.00457	CcSEcCtD
Metoclopramide—Urticaria—Simvastatin—atherosclerosis	0.0012	0.00457	CcSEcCtD
Metoclopramide—Body temperature increased—Simvastatin—atherosclerosis	0.00119	0.00455	CcSEcCtD
Metoclopramide—Headache—Rosuvastatin—atherosclerosis	0.00119	0.00455	CcSEcCtD
Metoclopramide—Hypersensitivity—Lovastatin—atherosclerosis	0.00119	0.00453	CcSEcCtD
Metoclopramide—Fatigue—Pravastatin—atherosclerosis	0.00118	0.00448	CcSEcCtD
Metoclopramide—Hypersensitivity—Ezetimibe—atherosclerosis	0.00117	0.00444	CcSEcCtD
Metoclopramide—Asthenia—Lovastatin—atherosclerosis	0.00116	0.00441	CcSEcCtD
Metoclopramide—Asthenia—Ezetimibe—atherosclerosis	0.00114	0.00433	CcSEcCtD
Metoclopramide—Nausea—Rosuvastatin—atherosclerosis	0.00113	0.00431	CcSEcCtD
Metoclopramide—Feeling abnormal—Pravastatin—atherosclerosis	0.00112	0.00429	CcSEcCtD
Metoclopramide—Hypersensitivity—Simvastatin—atherosclerosis	0.00111	0.00424	CcSEcCtD
Metoclopramide—Diarrhoea—Lovastatin—atherosclerosis	0.0011	0.00421	CcSEcCtD
Metoclopramide—Urticaria—Niacin—atherosclerosis	0.0011	0.0042	CcSEcCtD
Metoclopramide—Body temperature increased—Niacin—atherosclerosis	0.0011	0.00418	CcSEcCtD
Metoclopramide—Urticaria—Pravastatin—atherosclerosis	0.00108	0.00413	CcSEcCtD
Metoclopramide—Asthenia—Simvastatin—atherosclerosis	0.00108	0.00413	CcSEcCtD
Metoclopramide—Diarrhoea—Ezetimibe—atherosclerosis	0.00108	0.00413	CcSEcCtD
Metoclopramide—Body temperature increased—Pravastatin—atherosclerosis	0.00108	0.00411	CcSEcCtD
Metoclopramide—Dizziness—Lovastatin—atherosclerosis	0.00107	0.00407	CcSEcCtD
Metoclopramide—Dizziness—Ezetimibe—atherosclerosis	0.00105	0.00399	CcSEcCtD
Metoclopramide—Diarrhoea—Simvastatin—atherosclerosis	0.00103	0.00394	CcSEcCtD
Metoclopramide—Hypersensitivity—Niacin—atherosclerosis	0.00102	0.00389	CcSEcCtD
Metoclopramide—Rash—Lovastatin—atherosclerosis	0.00102	0.00388	CcSEcCtD
Metoclopramide—Dermatitis—Lovastatin—atherosclerosis	0.00102	0.00387	CcSEcCtD
Metoclopramide—Headache—Lovastatin—atherosclerosis	0.00101	0.00385	CcSEcCtD
Metoclopramide—Hypersensitivity—Pravastatin—atherosclerosis	0.001	0.00383	CcSEcCtD
Metoclopramide—Dizziness—Simvastatin—atherosclerosis	0.000998	0.0038	CcSEcCtD
Metoclopramide—Rash—Ezetimibe—atherosclerosis	0.000997	0.0038	CcSEcCtD
Metoclopramide—Dermatitis—Ezetimibe—atherosclerosis	0.000997	0.0038	CcSEcCtD
Metoclopramide—Asthenia—Niacin—atherosclerosis	0.000994	0.00379	CcSEcCtD
Metoclopramide—Headache—Ezetimibe—atherosclerosis	0.000991	0.00378	CcSEcCtD
Metoclopramide—Asthenia—Pravastatin—atherosclerosis	0.000979	0.00373	CcSEcCtD
Metoclopramide—Nausea—Lovastatin—atherosclerosis	0.000958	0.00365	CcSEcCtD
Metoclopramide—Rash—Simvastatin—atherosclerosis	0.000951	0.00363	CcSEcCtD
Metoclopramide—Dermatitis—Simvastatin—atherosclerosis	0.00095	0.00362	CcSEcCtD
Metoclopramide—Diarrhoea—Niacin—atherosclerosis	0.000948	0.00361	CcSEcCtD
Metoclopramide—Headache—Simvastatin—atherosclerosis	0.000945	0.0036	CcSEcCtD
Metoclopramide—Nausea—Ezetimibe—atherosclerosis	0.00094	0.00358	CcSEcCtD
Metoclopramide—Diarrhoea—Pravastatin—atherosclerosis	0.000933	0.00356	CcSEcCtD
Metoclopramide—Dizziness—Niacin—atherosclerosis	0.000916	0.00349	CcSEcCtD
Metoclopramide—Dizziness—Pravastatin—atherosclerosis	0.000902	0.00344	CcSEcCtD
Metoclopramide—Nausea—Simvastatin—atherosclerosis	0.000896	0.00342	CcSEcCtD
Metoclopramide—Rash—Niacin—atherosclerosis	0.000873	0.00333	CcSEcCtD
Metoclopramide—Dermatitis—Niacin—atherosclerosis	0.000873	0.00333	CcSEcCtD
Metoclopramide—Headache—Niacin—atherosclerosis	0.000868	0.00331	CcSEcCtD
Metoclopramide—Rash—Pravastatin—atherosclerosis	0.00086	0.00328	CcSEcCtD
Metoclopramide—Dermatitis—Pravastatin—atherosclerosis	0.000859	0.00328	CcSEcCtD
Metoclopramide—Headache—Pravastatin—atherosclerosis	0.000854	0.00326	CcSEcCtD
Metoclopramide—Nausea—Niacin—atherosclerosis	0.000823	0.00314	CcSEcCtD
Metoclopramide—Nausea—Pravastatin—atherosclerosis	0.00081	0.00309	CcSEcCtD
Metoclopramide—DRD3—Signaling Pathways—CCR2—atherosclerosis	5.89e-05	0.000158	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CCL5—atherosclerosis	5.88e-05	0.000158	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CYBA—atherosclerosis	5.87e-05	0.000157	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—INS—atherosclerosis	5.83e-05	0.000156	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CG—atherosclerosis	5.81e-05	0.000156	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CNR2—atherosclerosis	5.8e-05	0.000155	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTGS2—atherosclerosis	5.8e-05	0.000155	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CXCL8—atherosclerosis	5.8e-05	0.000155	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MMP3—atherosclerosis	5.79e-05	0.000155	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PLAT—atherosclerosis	5.74e-05	0.000154	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PARP1—atherosclerosis	5.74e-05	0.000154	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GHRL—atherosclerosis	5.74e-05	0.000154	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PRKCG—atherosclerosis	5.72e-05	0.000153	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ALB—atherosclerosis	5.71e-05	0.000153	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MMP9—atherosclerosis	5.69e-05	0.000152	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CNR2—atherosclerosis	5.68e-05	0.000152	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CXCL8—atherosclerosis	5.67e-05	0.000152	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MMP3—atherosclerosis	5.66e-05	0.000152	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	5.65e-05	0.000151	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—FABP4—atherosclerosis	5.63e-05	0.000151	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LCAT—atherosclerosis	5.63e-05	0.000151	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NFKB1—atherosclerosis	5.63e-05	0.000151	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PRKCG—atherosclerosis	5.59e-05	0.00015	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK8—atherosclerosis	5.53e-05	0.000148	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOA4—atherosclerosis	5.53e-05	0.000148	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AKT1—atherosclerosis	5.52e-05	0.000148	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—F2—atherosclerosis	5.52e-05	0.000148	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EDN1—atherosclerosis	5.5e-05	0.000147	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—NOS3—atherosclerosis	5.46e-05	0.000146	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL5—atherosclerosis	5.46e-05	0.000146	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP7A1—atherosclerosis	5.43e-05	0.000145	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EDN1—atherosclerosis	5.39e-05	0.000144	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL5—atherosclerosis	5.34e-05	0.000143	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ALB—atherosclerosis	5.34e-05	0.000143	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CG—atherosclerosis	5.28e-05	0.000141	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PRKCG—atherosclerosis	5.19e-05	0.000139	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VWF—atherosclerosis	5.17e-05	0.000138	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOC3—atherosclerosis	5.14e-05	0.000138	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—NOS3—atherosclerosis	5.11e-05	0.000137	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VEGFA—atherosclerosis	5.11e-05	0.000137	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LDLR—atherosclerosis	5.11e-05	0.000137	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PRKCG—atherosclerosis	5.08e-05	0.000136	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VWF—atherosclerosis	5.06e-05	0.000136	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—STAT3—atherosclerosis	5.06e-05	0.000135	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KNG1—atherosclerosis	5.04e-05	0.000135	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AGT—atherosclerosis	5.03e-05	0.000135	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOC3—atherosclerosis	5.03e-05	0.000135	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP27A1—atherosclerosis	5.02e-05	0.000134	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AGTR1—atherosclerosis	5.01e-05	0.000134	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LDLR—atherosclerosis	5e-05	0.000134	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTGS2—atherosclerosis	5e-05	0.000134	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL3—atherosclerosis	4.99e-05	0.000134	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AGT—atherosclerosis	4.92e-05	0.000132	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL2—atherosclerosis	4.92e-05	0.000132	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PLG—atherosclerosis	4.88e-05	0.000131	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL3—atherosclerosis	4.88e-05	0.000131	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK3—atherosclerosis	4.83e-05	0.000129	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NCF1—atherosclerosis	4.78e-05	0.000128	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOA2—atherosclerosis	4.76e-05	0.000127	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	4.76e-05	0.000127	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALOX15—atherosclerosis	4.76e-05	0.000127	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	4.76e-05	0.000127	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ABCG5—atherosclerosis	4.7e-05	0.000126	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TGFB1—atherosclerosis	4.69e-05	0.000126	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NCF1—atherosclerosis	4.67e-05	0.000125	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTGS2—atherosclerosis	4.67e-05	0.000125	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—F2—atherosclerosis	4.65e-05	0.000125	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SOCS3—atherosclerosis	4.62e-05	0.000124	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AGT—atherosclerosis	4.57e-05	0.000122	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—F2—atherosclerosis	4.55e-05	0.000122	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LPA—atherosclerosis	4.54e-05	0.000122	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCR2—atherosclerosis	4.51e-05	0.000121	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EDNRA—atherosclerosis	4.51e-05	0.000121	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CYBA—atherosclerosis	4.49e-05	0.00012	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AGT—atherosclerosis	4.47e-05	0.00012	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP3—atherosclerosis	4.47e-05	0.00012	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CG—atherosclerosis	4.45e-05	0.000119	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF2—atherosclerosis	4.45e-05	0.000119	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EDNRA—atherosclerosis	4.41e-05	0.000118	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCR2—atherosclerosis	4.41e-05	0.000118	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—BGN—atherosclerosis	4.4e-05	0.000118	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GHRL—atherosclerosis	4.39e-05	0.000118	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PLAT—atherosclerosis	4.39e-05	0.000118	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PARP1—atherosclerosis	4.39e-05	0.000118	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CYBA—atherosclerosis	4.39e-05	0.000118	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CG—atherosclerosis	4.35e-05	0.000117	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOA5—atherosclerosis	4.35e-05	0.000117	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOB—atherosclerosis	4.32e-05	0.000116	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GHRL—atherosclerosis	4.3e-05	0.000115	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PLAT—atherosclerosis	4.3e-05	0.000115	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PARP1—atherosclerosis	4.3e-05	0.000115	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCL8—atherosclerosis	4.28e-05	0.000115	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EDN1—atherosclerosis	4.25e-05	0.000114	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—F2—atherosclerosis	4.22e-05	0.000113	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL5—atherosclerosis	4.22e-05	0.000113	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	4.19e-05	0.000112	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—F2—atherosclerosis	4.13e-05	0.000111	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LPL—atherosclerosis	4.12e-05	0.00011	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALOX5—atherosclerosis	4.05e-05	0.000108	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CG—atherosclerosis	4.04e-05	0.000108	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PRKCG—atherosclerosis	4.01e-05	0.000107	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CG—atherosclerosis	3.95e-05	0.000106	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SPP1—atherosclerosis	3.9e-05	0.000105	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCL8—atherosclerosis	3.89e-05	0.000104	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KNG1—atherosclerosis	3.86e-05	0.000103	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AGTR1—atherosclerosis	3.83e-05	0.000103	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KNG1—atherosclerosis	3.78e-05	0.000101	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL2—atherosclerosis	3.76e-05	0.000101	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AGTR1—atherosclerosis	3.75e-05	0.000101	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PLG—atherosclerosis	3.74e-05	0.0001	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL2—atherosclerosis	3.68e-05	9.86e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PLG—atherosclerosis	3.66e-05	9.8e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NAMPT—atherosclerosis	3.63e-05	9.72e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PDGFB—atherosclerosis	3.61e-05	9.68e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LIPC—atherosclerosis	3.61e-05	9.66e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOC3—atherosclerosis	3.58e-05	9.6e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LDLR—atherosclerosis	3.56e-05	9.54e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SOCS3—atherosclerosis	3.54e-05	9.48e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—atherosclerosis	3.53e-05	9.46e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AGT—atherosclerosis	3.53e-05	9.45e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CETP—atherosclerosis	3.48e-05	9.32e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SOCS3—atherosclerosis	3.46e-05	9.28e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LEP—atherosclerosis	3.46e-05	9.26e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOE—atherosclerosis	3.46e-05	9.26e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CAV1—atherosclerosis	3.42e-05	9.17e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP3—atherosclerosis	3.42e-05	9.16e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOA1—atherosclerosis	3.42e-05	9.15e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF2—atherosclerosis	3.4e-05	9.12e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP3—atherosclerosis	3.34e-05	8.96e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SCARB1—atherosclerosis	3.33e-05	8.93e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF2—atherosclerosis	3.33e-05	8.92e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOB—atherosclerosis	3.3e-05	8.85e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ESR1—atherosclerosis	3.3e-05	8.84e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL8—atherosclerosis	3.28e-05	8.77e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—atherosclerosis	3.26e-05	8.73e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—F2—atherosclerosis	3.26e-05	8.73e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EDN1—atherosclerosis	3.25e-05	8.71e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOB—atherosclerosis	3.23e-05	8.66e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL5—atherosclerosis	3.23e-05	8.64e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL8—atherosclerosis	3.21e-05	8.59e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EDN1—atherosclerosis	3.18e-05	8.52e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL5—atherosclerosis	3.16e-05	8.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LPL—atherosclerosis	3.15e-05	8.45e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HMGCR—atherosclerosis	3.15e-05	8.43e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CG—atherosclerosis	3.12e-05	8.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LPL—atherosclerosis	3.09e-05	8.27e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PRKCG—atherosclerosis	3.07e-05	8.22e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PRKCG—atherosclerosis	3e-05	8.04e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SPP1—atherosclerosis	2.99e-05	8e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK3—atherosclerosis	2.99e-05	8e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL8—atherosclerosis	2.97e-05	7.97e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—INS—atherosclerosis	2.95e-05	7.91e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SPP1—atherosclerosis	2.92e-05	7.83e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—atherosclerosis	2.91e-05	7.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL8—atherosclerosis	2.91e-05	7.8e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL2—atherosclerosis	2.9e-05	7.78e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1—atherosclerosis	2.85e-05	7.65e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ABCA1—atherosclerosis	2.8e-05	7.51e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PDGFB—atherosclerosis	2.76e-05	7.41e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SERPINE1—atherosclerosis	2.71e-05	7.26e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PDGFB—atherosclerosis	2.71e-05	7.25e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AGT—atherosclerosis	2.7e-05	7.23e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LEP—atherosclerosis	2.64e-05	7.08e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOE—atherosclerosis	2.64e-05	7.08e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AGT—atherosclerosis	2.64e-05	7.08e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CAV1—atherosclerosis	2.62e-05	7.02e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOA1—atherosclerosis	2.61e-05	7e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NOS3—atherosclerosis	2.59e-05	6.94e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOE—atherosclerosis	2.59e-05	6.93e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LEP—atherosclerosis	2.59e-05	6.93e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CAV1—atherosclerosis	2.56e-05	6.87e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOA1—atherosclerosis	2.56e-05	6.85e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ESR1—atherosclerosis	2.52e-05	6.76e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—atherosclerosis	2.51e-05	6.73e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—F2—atherosclerosis	2.49e-05	6.68e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ESR1—atherosclerosis	2.47e-05	6.62e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—F2—atherosclerosis	2.44e-05	6.54e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HMOX1—atherosclerosis	2.41e-05	6.45e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	2.39e-05	6.39e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—atherosclerosis	2.35e-05	6.29e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CG—atherosclerosis	2.34e-05	6.26e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOB—atherosclerosis	2.3e-05	6.17e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL8—atherosclerosis	2.3e-05	6.15e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	2.29e-05	6.12e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—INS—atherosclerosis	2.26e-05	6.05e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTM1—atherosclerosis	2.24e-05	6.01e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK3—atherosclerosis	2.24e-05	5.99e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL2—atherosclerosis	2.22e-05	5.95e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—atherosclerosis	2.22e-05	5.94e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—INS—atherosclerosis	2.21e-05	5.92e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LPL—atherosclerosis	2.2e-05	5.9e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1—atherosclerosis	2.18e-05	5.85e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—atherosclerosis	2.18e-05	5.85e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL2—atherosclerosis	2.17e-05	5.83e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GPX1—atherosclerosis	2.15e-05	5.75e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1—atherosclerosis	2.14e-05	5.73e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CD36—atherosclerosis	2.09e-05	5.6e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—atherosclerosis	2.08e-05	5.56e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	2.07e-05	5.56e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NFKB1—atherosclerosis	2.05e-05	5.51e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	2.03e-05	5.44e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK8—atherosclerosis	2.02e-05	5.41e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—atherosclerosis	2.01e-05	5.4e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.98e-05	5.31e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOS3—atherosclerosis	1.98e-05	5.31e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARA—atherosclerosis	1.94e-05	5.21e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOS3—atherosclerosis	1.94e-05	5.19e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AGT—atherosclerosis	1.88e-05	5.04e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—atherosclerosis	1.86e-05	5e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT3—atherosclerosis	1.85e-05	4.95e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOE—atherosclerosis	1.84e-05	4.94e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CAV1—atherosclerosis	1.83e-05	4.9e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOA1—atherosclerosis	1.82e-05	4.88e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK3—atherosclerosis	1.76e-05	4.73e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.76e-05	4.71e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	1.72e-05	4.61e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TGFB1—atherosclerosis	1.71e-05	4.59e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.7e-05	4.55e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.67e-05	4.48e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.66e-05	4.46e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	1.66e-05	4.45e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—atherosclerosis	1.64e-05	4.38e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARG—atherosclerosis	1.61e-05	4.3e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—atherosclerosis	1.59e-05	4.26e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—INS—atherosclerosis	1.58e-05	4.22e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NFKB1—atherosclerosis	1.57e-05	4.21e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—atherosclerosis	1.56e-05	4.17e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK8—atherosclerosis	1.55e-05	4.14e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—atherosclerosis	1.54e-05	4.13e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	1.54e-05	4.12e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	1.51e-05	4.05e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	1.51e-05	4.04e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALB—atherosclerosis	1.44e-05	3.87e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—atherosclerosis	1.43e-05	3.82e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT3—atherosclerosis	1.41e-05	3.79e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	1.4e-05	3.74e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT3—atherosclerosis	1.38e-05	3.7e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NOS3—atherosclerosis	1.38e-05	3.7e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK3—atherosclerosis	1.35e-05	3.62e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	1.32e-05	3.54e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TGFB1—atherosclerosis	1.31e-05	3.51e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—atherosclerosis	1.29e-05	3.46e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	1.28e-05	3.43e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.26e-05	3.39e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—atherosclerosis	1.19e-05	3.19e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—atherosclerosis	9.87e-06	2.64e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—atherosclerosis	9.66e-06	2.59e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—atherosclerosis	9.1e-06	2.44e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—atherosclerosis	8.91e-06	2.39e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—atherosclerosis	6.35e-06	1.7e-05	CbGpPWpGaD
